Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to ...

Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.

CSL has priced US$1.5 billion of corporate bonds in the United States, turning to offshore debt markets to refinance its ...

An experimental treatment being developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit held for three months after treatment stopped, ...

Seven leading Chinese medical societies have jointly published an expert consensus naming Technegas the preferred ventilation agent for lung imaging in pulmonary embolism, handing the Sydney ...

An Australian company has taken one of the country's top design honours for a machine built to solve one of healthcare's most stubborn cleaning problems.

Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.